UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/706,081	11/13/2003	Nathan Ravi	111828-00110	7277
27557 BLANK ROME	7590 09/03/200 E LLP	8	EXAMINER	
600 NEW HAMPSHIRE AVENUE, N.W.			ROBERTS, LEZAH	
WASHINGTON, DC 20037			ART UNIT	PAPER NUMBER
			1612	
			MAIL DATE	DELIVERY MODE
			09/03/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	10/706,081	RAVI, NATHAN					
Office Action Summary	Examiner	Art Unit					
	LEZAH W. ROBERTS	1612					
The MAILING DATE of this communic Period for Reply	ation appears on the cover sheet wit	h the correspondence address					
A SHORTENED STATUTORY PERIOD FOWHICHEVER IS LONGER, FROM THE MA - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commu. - If NO period for reply is specified above, the maximum statt - Failure to reply within the set or extended period for reply whan yeply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	ALING DATE OF THIS COMMUNIC f 37 CFR 1.136(a). In no event, however, may a re nication. utory period will apply and will expire SIX (6) MONT rill, by statute, cause the application to become ABA	ATION. ply be timely filed THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed	on 12 June 2008.						
<u></u>							
·—	, 						
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-27,29-39 and 45-121</u> is/are	e pending in the application.						
• • • • • • • • • • • • • • • • • • • •	4a) Of the above claim(s) <u>1-22,30,32,33,46-116 and 119-121</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) 23-27,29,31,34-39,45,117 ai	5)⊠ Claim(s) <u>23-27,29,31,34-39,45,117 and 118</u> is/are rejected.						
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restricti	on and/or election requirement.						
Application Papers							
9)☐ The specification is objected to by the	Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to	by the Examiner. Note the attached	Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
<u> </u>	locuments have been received. locuments have been received in Ap f the priority documents have been i al Bureau (PCT Rule 17.2(a)).	oplication No received in this National Stage					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	O-948) Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application _·					

DETAILED ACTION

This Office Action is in response to the Amendment filed June 12, 2008. All previous rejections have been withdrawn unless stated below.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Status: Claims 119 and 120 were previously withdrawn because they are drawn to a non-elected species but were inadvertently left out of the listing of claims that are withdrawn in the previous office action.

Claims

Claim Rejections - 35 USC § 103 - Obviousness

1) Claims 23-29, 31, 34-39, 44, 45 and 117-118 were rejected under 35 U.S.C. 103(a) as being unpatentable over Marchant (US 2002/0068087) in view of Viegas et al. (US 2003/0143274). The rejection is maintained. Claims 28 and 44 have been cancelled.

Applicant's Arguments

Art Unit: 1612

Applicant argues the combination of Marchant and Viegas et al. do not disclose all the limitations of the instant claims. The application by Marchant does not contemplate *in situ* gelation. Marchant also discloses a degradable hydrogel, which is not desirable to use as a lens replacement. This teaches away from the present invention. Furthermore, Viegas does not disclose lens replacement. This argument is not persuasive.

Examiner's Response

The claims are drawn to forming a hydrogel in the capsular sac and do not disclose that the hydrogel is used to make a permanent lens as argued by Applicant. The secondary reference gives the motivation as to why one of skill in the art would want to form the hydrogel *in situ* as opposed to outside the eye. Therefore the two references together encompass all the limitation of the instant claims and do not teach away from the instant claims.

2) Claims 24, 26-29, 31 and 34-39 were rejected under 35 U.S.C. 103(a) as being unpatentable over Sawhney (US 6,818,018) in view of Marchant (US 2002/0068087). The rejection is maintained. Claim 28 has been cancelled.

Applicant's Arguments

Applicant argues Sawhney and Marchant do not disclose every element of the instant claims. Sawhney discloses hydrogels that are not permanent. The instant claims

require injecting the hydrogel into the capsular bag and *in situ* gelating the solution to form a lens replacement inside the capsular bag. Marchant does not remedy the deficiencies of Sawhney. This argument is not persuasive.

Examiner's Response

The claims do not recite the limitation that the hydrogels are permanent and make a lens inside the capsular bag. The claims recite a method of forming a hydrogel in an eye, which is encompassed by the combined references. In regards to the capsular bag, the secondary reference discloses introducing the gel forming solution into the eye (paragraph 0015) and using the solutions to deliver actives (paragraph 0015). Sawhney also discloses using the disclosed compositions for delivering drugs to the body. Therefore it would have been obvious to insert the composition of the combination of Sawhney and Marchant into the eye or capsular bag in order to deliver therapeutic agents to the eye when desired.

Claims 23, 24, 26-29, 31, 34-39, 45, 117 and 118 are rejected.

Claims 1-22, 30, 32, 33, 46-116 and 119-121 are withdrawn.

No claims allowed.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH W. ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached on 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick F. Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/706,081

Art Unit: 1612

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/L. W. R./ Examiner, Art Unit 1612

/Frederick Krass/

Supervisory Patent Examiner, Art Unit 1612